Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (3024)	7/13/2010 1:42:10 PM
From: mlkr	Read Replies (2) \| Respond to of 3722

TBRN Pfizer to develop 1 of 2 Trubion arthritis drugs SAN FRANCISCO (MarketWatch) -- Trubion Pharmaceuticals Inc. /quotes/comstock/15!trbn/quotes/nls/trbn (TRBN 2.57, -0.16, -5.86%) said late Monday that Pfizer Inc. /quotes/comstock/13!pfe/quotes/nls/pfe (PFE 14.84, -0.09, -0.60%) will continue developing one of its rheumatoid arthritis drug candidates but will halt development of another. Shares of Trubion were halted prior to the announcement, and had last traded down 1.5% to $3.66. Following mid-stage clinical trials, Pfizer chose to keep developing Trubion's SBI-087 drug and not develop its TRU-015, Trubion said.